Výsledky vyhledávání - "Martin G Sanda"

Akademický článek

The diagnostic challenges of differentiating metastatic extramammary Paget disease and prostatic adenocarcinoma: A case report and review of the literature

Autor: Gregory Palmateer, Edouard H. Nicaise, Jatin Gandhi, Taylor Goodstein, Michelle Sheng, Kenneth Ogan, Omer Kucuk, Melinda Yushak, Martin G. Sanda, Keith A. Delman, Viraj Master

Publikováno v: Urology Case Reports, Vol 57, Iss , Pp 102875- (2024)

Extramammary Paget disease (EMPD) is a rare dermatologic malignancy with a high rate of recurrence and increased risk for developing secondary malignancies. We present a 74-year-old male with previously resected primary EMPD who presented with widesp

Externí odkaz: https://doaj.org/article/f652448fcc094338be5d8f4b73b7de89

Zobrazit plný text záznamu

Akademický článek

Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.

Autor: Haydn T Kissick, Martin G Sanda, Laura K Dunn, Mohamed S Arredouani

Publikováno v: PLoS ONE, Vol 9, Iss 4, p e93231 (2014)

Here, we sought to determine whether peptide vaccines designed harbor both class I as well as class II restricted antigenic motifs could concurrently induce CD4 and CD8 T cell activation against autologous tumor antigens. Based on our prior genome-wi

Externí odkaz: https://doaj.org/article/51372bfb418a40bf819d2b00698f5e0f

Zobrazit plný text záznamu

Akademický článek

The role of the transcription factor SIM2 in prostate cancer.

Autor: Bin Lu, John M Asara, Martin G Sanda, Mohamed S Arredouani

Publikováno v: PLoS ONE, Vol 6, Iss 12, p e28837 (2011)

Recent reports have suggested a possible involvement of Single-minded homolog 2 (SIM2) in human solid cancers, including prostate cancer. However, the exact role of SIM2 in cancer in general, and in prostate cancer in particular, remains largely unkn

Externí odkaz: https://doaj.org/article/064c666e3a724828a8e06623ae321ff7

Zobrazit plný text záznamu

Akademický článek

Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.

Autor: Michael Nowak, Mohammed S Arredouani, Adrian Tun-Kyi, Ingo Schmidt-Wolf, Martin G Sanda, Steven P Balk, Mark A Exley

Publikováno v: PLoS ONE, Vol 5, Iss 6, p e11311 (2010)

Numerical and functional defects of invariant natural killer T cells (iNKT) have been documented in human and mouse cancers, resulting in a defect in IFN production in several malignancies. iNKT cells recognize glycolipids presented on CD1d molecules

Externí odkaz: https://doaj.org/article/93aa2fff4c9f40ef9fa68fef02e3c611

Zobrazit plný text záznamu

Akademický článek

Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci

Publikováno v: JCI Insight, Vol 7, Iss 4 (2022)

BACKGROUND Prostate cancer is multifocal with distinct molecular subtypes. The utility of genomic subtyping has been challenged due to inter- and intrafocal heterogeneity. We sought to characterize the subtype-defining molecular alterations of primar

Externí odkaz: https://doaj.org/article/c79b0c37b3564a8a9e8aad713f06f212

Zobrazit plný text záznamu

Akademický článek

Genetic factors associated with prostate cancer conversion from active surveillance to treatment

Autor: Yu Jiang, Travis J. Meyers, Adaeze A. Emeka, Lauren Folgosa Cooley, Phillip R. Cooper, Nicola Lancki, Irene Helenowski, Linda Kachuri, Daniel W. Lin, Janet L. Stanford, Lisa F. Newcomb, Suzanne Kolb, Antonio Finelli, Neil E. Fleshner, Maria Komisarenko, James A. Eastham, Behfar Ehdaie, Nicole Benfante, Christopher J. Logothetis, Justin R. Gregg, Cherie A. Perez, Sergio Garza, Jeri Kim, Leonard S. Marks, Merdie Delfin, Danielle Barsa, Danny Vesprini, Laurence H. Klotz, Andrew Loblaw, Alexandre Mamedov, S. Larry Goldenberg, Celestia S. Higano, Maria Spillane, Eugenia Wu, H. Ballentine Carter, Christian P. Pavlovich, Mufaddal Mamawala, Tricia Landis, Peter R. Carroll, June M. Chan, Matthew R. Cooperberg, Janet E. Cowan, Todd M. Morgan, Javed Siddiqui, Rabia Martin, Eric A. Klein, Karen Brittain, Paige Gotwald, Daniel A. Barocas, Jeremiah R. Dallmer, Jennifer B. Gordetsky, Pam Steele, Shilajit D. Kundu, Jazmine Stockdale, Monique J. Roobol, Lionne D.F. Venderbos, Martin G. Sanda, Rebecca Arnold, Dattatraya Patil, Christopher P. Evans, Marc A. Dall’Era, Anjali Vij, Anthony J. Costello, Ken Chow, Niall M. Corcoran, Soroush Rais-Bahrami, Courtney Phares, Douglas S. Scherr, Thomas Flynn, R. Jeffrey Karnes, Michael Koch, Courtney Rose Dhondt, Joel B. Nelson, Dawn McBride, Michael S. Cookson, Kelly L. Stratton, Stephen Farriester, Erin Hemken, Walter M. Stadler, Tuula Pera, Deimante Banionyte, Fernando J. Bianco, Jr., Isabel H. Lopez, Stacy Loeb, Samir S. Taneja, Nataliya Byrne, Christopher L. Amling, Ann Martinez, Luc Boileau, Franklin D. Gaylis, Jacqueline Petkewicz, Nicholas Kirwen, Brian T. Helfand, Jianfeng Xu, Denise M. Scholtens, William J. Catalona, John S. Witte

Publikováno v: HGG Advances, Vol 3, Iss 1, Pp 100070- (2022)

Summary: Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for PC, many men on AS eventually convert to active

Externí odkaz: https://doaj.org/article/dd671a3166f5492e9f3db2429cd59265

Zobrazit plný text záznamu

Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model

Autor: Bindu Varghese, Lydia Lynch, Lianne E. Vriend, Dobrin Draganov, Justice M. Clark, Haydn T. Kissick, Sharlin Varghese, Martin G. Sanda, Glenn Dranoff, M. Simo Arredouani, Steven P. Balk, Mark A. Exley

Publikováno v: Varghese, B, Lynch, L, Vriend, L E, Draganov, D, Clark, J M, Kissick, H T, Varghese, S, Sanda, M G, Dranoff, G, Arredouani, M S, Balk, S P & Exley, M A 2022, ' Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model ', Cancer Immunology, Immunotherapy, vol. 71, no. 12, pp. 2943-2955 . https://doi.org/10.1007/s00262-022-03210-8
Cancer Immunology, Immunotherapy, 71(12), 2943-2955. Springer Science and Business Media Deutschland GmbH

Invariant natural killer T cells (iNKT cells) express a semi-invariant T cell receptor that recognizes certain glycolipids (including α-galactosylceramide, αGC) bound to CD1d, and can induce potent antitumor responses. Here, we assessed whether αG

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a096f8da2884cfb2bc0afcb284506317
http://www.scopus.com/inward/record.url?scp=85129666255&partnerID=8YFLogxK

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání